Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation ExpenseEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares RepurchasedShort-Term Debt issuances
Ratios

Collegium Pharmaceutical (COLL) Shares Repurchased (2021 - 2024)

Collegium Pharmaceutical has reported Shares Repurchased over the past 4 years, most recently at $25.0 million for Q4 2024.

  • For Q4 2024, Shares Repurchased changed 0.1% year-over-year to $25.0 million; the TTM value through Dec 2025 reached $25.0 million, down 56.6%, while the annual FY2025 figure was $25.1 million, 58.18% down from the prior year.
  • Shares Repurchased for Q4 2024 was $25.0 million at Collegium Pharmaceutical, roughly flat from $25.0 million in the prior quarter.
  • Over five years, Shares Repurchased peaked at $32.3 million in Q4 2021 and troughed at $7.6 million in Q4 2022.
  • A 4-year average of $22.5 million and a median of $25.0 million in 2023 define the central range for Shares Repurchased.
  • Biggest five-year swings in Shares Repurchased: tumbled 76.37% in 2022 and later soared 227.18% in 2023.
  • Year by year, Shares Repurchased stood at $32.3 million in 2021, then tumbled by 76.37% to $7.6 million in 2022, then soared by 227.18% to $25.0 million in 2023, then increased by 0.1% to $25.0 million in 2024.
  • Business Quant data shows Shares Repurchased for COLL at $25.0 million in Q4 2024, $25.0 million in Q4 2023, and $7.6 million in Q4 2022.